Participated · Equity · Sep 2023

Founded in 2009 by Dr Karl Tryggvason and Kristian Tryggvason, BioLamina produces full-length, chemically defined, animal origin-free human recombinant laminins (Biolaminin®) used to support controlled cell culture systems. Its substrates are designed to enable reliable growth and differentiation of pluripotent stem cells and other primary cells and are used in cell therapy development, including phase I–III clinical trials. The company emphasizes scalable, high-quality cell culture solutions to improve consistency for cell therapies and drug testing. BioLamina recently secured a €20 million venture debt loan from the European Investment Bank to expand manufacturing capacity, optimise processes, broaden its product portfolio and strengthen its technological base. The financing is intended to extend the company’s funding runway while minimising immediate equity dilution.

Participated · Equity · Jun 2017

Yubico designs and sells YubiKey two-factor authentication hardware keys and the YubiHSM security module for protecting servers. The company plans to expand its platform beyond authentication into advanced software and services for IoT, payments, and server encryption. It intends to use the new funding to scale product development and grow its team. Yubico has partnered with major online service providers and reports nine of the top ten internet companies as YubiKey users, with partners including Facebook, Google, GitHub, Salesforce, Atlassian, Dropbox, Dashlane, and Docker. The company has offices in Sweden, the U.K., Germany, the United States, Australia, and Singapore. Prior to this round Yubico had raised $4.5M from angel investors and recently secured a $30M institutional funding round.